Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
850 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT01503632 | Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission | completed | Phase 3 | 570 | Children's Oncology GroupNETWORK | 2 | Jul 31, 2026 |
| clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT02152982 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | active not recruiting | Phase 2 / Phase 3 | 447 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation(CheckMate 9DX) | active not recruiting | Phase 3 | 545 | Bristol-Myers SquibbINDUSTRY | 25 | Jul 31, 2026 | clinicaltrials |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | active not recruiting | Phase 3 | 813 | National Cancer Institute (NCI)NIH | 5 | Jul 31, 2026 | clinicaltrials |
| NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 681 | Astellas Pharma IncINDUSTRY | 7 | Jul 31, 2026 | clinicaltrials |
| NCT02981628 | Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 80 | Children's Oncology GroupNETWORK | 2 | Jul 30, 2026 | clinicaltrials |
| NCT03914625 | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | active not recruiting | Phase 3 | 6,720 | National Cancer Institute (NCI)NIH | 5 | Jul 30, 2026 | clinicaltrials |
| NCT04195399 | A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery | active not recruiting | Phase 2 | 31 | Children's Oncology GroupNETWORK | 5 | Jul 30, 2026 | clinicaltrials |
| NCT04994132 | A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma | active not recruiting | Phase 3 | 113 | Children's Oncology GroupNETWORK | 5 | Jul 30, 2026 | clinicaltrials |
| NCT05896189 | Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | active not recruiting | N/A | 386 | NRG OncologyOTHER | 2 | Jul 30, 2026 | clinicaltrials |
| NCT00644228 | Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma | active not recruiting | Phase 3 | 525 | National Cancer Institute (NCI)NIH | 3 | Jul 29, 2026 | clinicaltrials |
| NCT02101853 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 669 | National Cancer Institute (NCI)NIH | 5 | Jul 29, 2026 | clinicaltrials |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | active not recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 3 | Jul 29, 2026 | clinicaltrials |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | active not recruiting | Phase 3 | 312 | National Cancer Institute (NCI)NIH | 3 | Jul 29, 2026 | clinicaltrials |
| NCT03785249 | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | active not recruiting | Phase 1 / Phase 2 | 731 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT04458831 | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)(IONA-MM) | completed | — | 583 | SanofiINDUSTRY | 21 | Jul 29, 2026 | clinicaltrials |
| NCT00379340 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor | completed | Phase 3 | 395 | Children's Oncology GroupNETWORK | 7 | Jul 24, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT06412029 | Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices(HRSN) | enrolling by invitation | — | 144 | Wake Forest University Health SciencesOTHER | 3 | Jul 24, 2026 | clinicaltrials |
| NCT05609370 | A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 4 | Jul 23, 2026 | clinicaltrials |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 291 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2026 | clinicaltrials |
| NCT03833154 | Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation(PACIFIC-4) | active not recruiting | Phase 3 | 724 | AstraZenecaINDUSTRY | 20 | Jul 20, 2026 | clinicaltrials |
| NCT02724579 | Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma | active not recruiting | Phase 2 | 45 | Children's Oncology GroupNETWORK | 5 | Jul 16, 2026 | clinicaltrials |
| NCT03581292 | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 5 | Jul 16, 2026 | clinicaltrials |
| NCT03817398 | Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia | active not recruiting | Phase 2 | 110 | Children's Oncology GroupNETWORK | 4 | Jul 16, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer(OlympiA) | active not recruiting | Phase 3 | 1,837 | AstraZenecaINDUSTRY | 24 | Jul 14, 2026 | clinicaltrials |
| NCT04939597 | A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor | active not recruiting | Phase 3 | 162 | Children's Oncology GroupNETWORK | 2 | Jul 13, 2026 | clinicaltrials |
| NCT05301842 | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC(EMERALD-3) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 22 | Jul 13, 2026 | clinicaltrials |
| NCT05874414 | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 98 | GenfitINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT06151197 | Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)(STRIDE) | completed | Phase 3 | 436 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT03919071 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | active not recruiting | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05303792 | Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 68 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT06096779 | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis(Kirros) | active not recruiting | Phase 2 | 30 | Genentech, Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT00904241 | Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma | completed | — | 10,000 | Children's Oncology GroupNETWORK | 8 | Jul 9, 2026 | clinicaltrials |
| NCT03603808 | VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions | completed | Phase 2 | 44 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05308446 | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | active not recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05409066 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma(EPCORE FL-1) | active not recruiting | Phase 3 | 549 | GenmabINDUSTRY | 30 | Jul 8, 2026 | clinicaltrials |
| NCT06562543 | A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | recruiting | Phase 4 | 78 | TakedaINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT06611553 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) | active not recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2026 | clinicaltrials |
| NCT04077463 | A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer(Chrysalis-2) | active not recruiting | Phase 1 | 701 | Janssen Research & Development, LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma(GOLSEEK-1) | active not recruiting | Phase 3 | 850 | CelgeneINDUSTRY | 38 | Jul 6, 2026 | clinicaltrials |
| NCT02193282 | Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) | active not recruiting | Phase 3 | 390 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT04214067 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | active not recruiting | Phase 3 | 164 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | completed | Phase 3 | 236 | National Cancer Institute (NCI)NIH | 6 | Jun 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials